Who are Solifenacin plus Tamsulosin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/solifenacin-plus-tamsulosin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Solifenacin plus Tamsulosin — Competitive Intelligence Brief

Solifenacin plus Tamsulosin (Solifenacin plus Tamsulosin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent + alpha-1A adrenergic antagonist combination. Area: Urology.

marketed Anticholinergic agent + alpha-1A adrenergic antagonist combination M3 muscarinic receptor; alpha-1A adrenergic receptor Urology Small molecule Live · refreshed every 30 min

Target snapshot

Solifenacin plus Tamsulosin (Solifenacin plus Tamsulosin) — Soonchunhyang University Hospital. Solifenacin blocks muscarinic receptors in the bladder to reduce overactive bladder symptoms, while tamsulosin relaxes smooth muscle in the prostate and urethra to improve urinary flow.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Solifenacin plus Tamsulosin TARGET	Solifenacin plus Tamsulosin	Soonchunhyang University Hospital	marketed	Anticholinergic agent + alpha-1A adrenergic antagonist combination	M3 muscarinic receptor; alpha-1A adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent + alpha-1A adrenergic antagonist combination class)

Soonchunhyang University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Solifenacin plus Tamsulosin — Competitive Intelligence Brief. https://druglandscape.com/ci/solifenacin-plus-tamsulosin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab